Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)
NCT ID: NCT03768427
Last Updated: 2024-05-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
454 participants
INTERVENTIONAL
2019-05-27
2021-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
NCT02550288
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
NCT01370603
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)
NCT02460159
MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)
NCT00092690
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)
NCT01370590
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EZ 10 mg/Ator 10 mg
Single oral dose of EZ10mg/Ator10mg FDC tablet once daily (QD) for 84 days
EZ 10 mg/Ator 10 mg
FDC of EZ10 mg/Ator 10mg
Placebo for FDC EZ/Ator
A single placebo tablet administered orally QD for 84 days
Atorvastatin 20 mg
2 atorvastatin 10 mg tablets administered orally, QD for 84 days
Atorvastatin
Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets
Placebo for atorvastatin
Two placebo tablets matching atorvastatin administered orally QD for 84 days
EZ 10 mg/Ator 20 mg
Single oral dose of EZ10mg/Ator20mg FDC tablet QD for 84 days
EZ 10 mg/Ator 20 mg
FDC of EZ10 mg/Ator 20mg
Placebo for FDC EZ/Ator
A single placebo tablet administered orally QD for 84 days
Atorvastatin 40 mg
2 atorvastatin 20 mg tablets administered orally, QD for 84 days
Atorvastatin
Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets
Placebo for atorvastatin
Two placebo tablets matching atorvastatin administered orally QD for 84 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EZ 10 mg/Ator 10 mg
FDC of EZ10 mg/Ator 10mg
EZ 10 mg/Ator 20 mg
FDC of EZ10 mg/Ator 20mg
Atorvastatin
Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets
Placebo for FDC EZ/Ator
A single placebo tablet administered orally QD for 84 days
Placebo for atorvastatin
Two placebo tablets matching atorvastatin administered orally QD for 84 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has been stabilized on atorvastatin treatment at 10 mg or 20 mg (or other statins with LDL-C lowering efficacy equivalent to atorvastatin) for at least 4 weeks prior to Visit 1.
* If female, is not pregnant or breastfeeding, and is either not a woman of childbearing potential (WOCBP), or is a WOCBP who has used a contraceptive consistent with local regulations.
* If male, has used a contraceptive consistent with local regulations.
* Agrees to maintain a stable diet and stable exercise during the study.
Exclusion Criteria
* Is currently treated with statin at dose of equivalent LDL-C lowering effect \>20 mg atorvastatin.
* Has active liver disease
* Has New York Heart Association (NYHA) Class III or IV symptomatic congestive heart failure at Visit 1.
* Has had uncontrolled cardiac arrhythmias, myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, unstable angina, or stroke within 3 months (12 weeks) prior to Visit 1.
* Has homozygous familial hypercholesterolemia or has undergone LDL apheresis.
* Has endocrine or metabolic disease known to influence serum lipids or lipoproteins (i.e., secondary causes of hyperlipidemia, e.g., hyper or hypothyroidism, Cushing's syndrome).
* Has had a gastrointestinal tract bypass, or other significant intestinal malabsorption.
* Has a history of cancer within the past 5 years from Visit 1 (except for successfully treated dermatological basal cell or squamous cell carcinoma or in situ cervical cancer).
* Is known to be human immunodeficiency virus (HIV) positive.
* Has hypersensitivity or intolerance to ezetimibe, atorvastatin, the ezetimibe/atorvastatin combination tablet, or any component of these medications or has a condition or situation, which is described as a contraindication in labeling of EZETROL or Lipitor or may interfere with participation in the study.
* Has disorders of the hematologic, digestive, or central nervous systems including cerebrovascular disease and degenerative disease that would limit study evaluation or participation.
* Has a history of mental instability, drug/alcohol abuse within the past 5 years, or major psychiatric illness not adequately controlled and stable on pharmacotherapy.
* Has a history of myopathy or rhabdomyolysis with ezetimibe or any statin.
* Is a WOCBP who has had a positive urine pregnancy test within 24 hours before the first dose of study intervention. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
* Is currently taking medications that are potent modulators of cytochrome P-450 3A4 (CYP3A4) including: cyclosporine, systemically administered azole antifungals (e.g., ketoconazole, fluconazole, and itraconazole), macrolide antibiotics (e.g., clarithromycin, and erythromycin), protease inhibitors (e.g., ritonavir, saquinavir, and lopinavir), grapefruit or juice of grapefruit (200 ml/day for \>3 times per week)
* Is taking any cyclical hormones (e.g., cyclical oral contraceptives, cyclical hormone replacement), including the combination of ethinyl estradiol and norethisterone, or non-cyclical hormones, including non-cyclical hormone replacement therapy (HRT) or any estrogen antagonist/agonist within 8 weeks.
* Note: If participant has been treated with a stable regimen of non-cyclical HRT for \> 8 weeks and agree to continue this regimen for the duration of the trial, concomitant therapy is acceptable.
* Is receiving treatment with systemic corticosteroids (intravenous, intramuscular and oral steroids).
* Is treated with psyllium, other fiber-based laxatives, phytosterol margarine, and herbal medicine and/or over the counter (OTC) therapies that are known to affect serum lipids.
* Note: If participant has been treated with a stable regimen for \> 8 weeks and agrees to continue this regimen for the duration of the trial, concomitant therapy is acceptable.
* Is treated with an anti-obesity drug (e.g. mazindol) within 12 weeks prior to Visit 1.
* Is treated with warfarin or warfarin-like anticoagulants and has not been on a stable dose with a stable International Normalized Ratio (INR) for at least 6 weeks.
weeks.
* Has taken lipid-lowering agents (except probucol) including, Cholestin, bile acid sequestrants, ezetimibe, fibrates or niacin (\>200 mg/day), proprotein convertases subtilisin/kexin type 9 (PCSK9) inhibitors within 6 weeks prior to Visit 1.
* Has taken probucol within 10 weeks prior to Visit 1.
* Has been treated with any other investigational drug within 30 days.
* Currently follows an excessive weight reduction diet.
* Currently engages in a vigorous exercise regimen (e.g., marathon training, body building training) or intends to start training during the study.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Organon and Co
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Baotou Medical College ( Site 0025)
Baotou, Anhui, China
Beijing Anzhen Hospital. Capital Medical University ( Site 0001)
Beijing, Anhui, China
Aero Space center hospital ( Site 0003)
Beijing, Beijing Municipality, China
Beijing Friendship Hospital ( Site 0005)
Beijing, Beijing Municipality, China
Chongqing General Hospital ( Site 0037)
Chongqing, Chongqing Municipality, China
Lanzhou University Second Hospital ( Site 0041)
Lanzhou, Gansu, China
Guangdong General Hospital ( Site 0006)
Guangzhou, Guangdong, China
The First Affiliated Hospital.Sun Yat-sen University ( Site 0007)
Guangzhou, Guangdong, China
Sun Yat-sen Memorial Hospital of Sun Yat-sen University ( Site 0008)
Guangzhou, Guangdong, China
Daqing Oilfield General Hospital ( Site 0010)
Daqing, Heilongjiang, China
The first affiliated Hospital of Harbin Medical University ( Site 0009)
Haerbin, Heilongjiang, China
The Third Xiangya Hospital of Central South University ( Site 0013)
Changsha, Hunan, China
Hunan Provincial People's Hospital ( Site 0011)
Changsha, Hunan, China
Zhongda Hospital Southeast University ( Site 0045)
Nanjing, Jiangsu, China
The Second Affiliated Hospital of Nanjing Medical University ( Site 0020)
Nanjing, Jiangsu, China
First Affiliated Hospital of Soochow University ( Site 0048)
Suzhou, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical University ( Site 0017)
Xuzhou, Jiangsu, China
Subei People's Hospital ( Site 0040)
Yangzhou, Jiangsu, China
Second Affiliated Hospital of Nanchang University ( Site 0038)
Nanchang, Jiangxi, China
Ji Lin Province People Hospital ( Site 0016)
Changchun, Jilin, China
China-Japan Union Hospital of Jilin University ( Site 0015)
Changchun, Jilin, China
Central People s Hospital of Siping ( Site 0046)
Siping, Jilin, China
The People's Hospital of Liaoning Province-Cardiovascular ( Site 0022)
Shenyang, Liaoning, China
Zhongshan Hospital Fudan University ( Site 0049)
Shanghai, Shanghai Municipality, China
Shanghai Tongji Hospital ( Site 0031)
Shanghai, Shanghai Municipality, China
Tianjin Union Medicine Centre ( Site 0032)
Tianjin, Tianjin Municipality, China
People s Hospital of Lishui City ( Site 0036)
Lishui, Zhejiang, China
Ningbo First Hospital ( Site 0042)
Ningbo, Zhejiang, China
Taizhou Hospital of Zhejiang Province ( Site 0035)
Taizhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University ( Site 0034)
Wenzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Qian J, Li Z, Zhang X, Chen J, Ding C, Yang P, Liu Y, Shi M, Ren X, Ge J; Phase III Study Investigators. Efficacy and Tolerability of Ezetimibe/Atorvastatin Fixed-dose Combination Versus Atorvastatin Monotherapy in Hypercholesterolemia: A Phase III, Randomized, Active-controlled Study in Chinese Patients. Clin Ther. 2022 Oct;44(10):1282-1296. doi: 10.1016/j.clinthera.2022.08.013. Epub 2022 Sep 29.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-0653C-439
Identifier Type: OTHER
Identifier Source: secondary_id
0653C-439
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.